Verrica Pharmaceuticals (VRCA) Jefferies 2024 Global Healthcare Conference summary

Financial and operational highlights

• Reported Q1 net revenues of $3.2 million, an increase from Q4, driven by higher demand and expanded distribution, including military channels.

• Product sales price is $685, with a gross-to-net in the 50% range.

• $49 million in cash at quarter-end, expected to fund operations into Q1 2025, excluding a $75 million debt facility available from OrbiMed.

• Operating expenses increased due to sales force expansion and R&D pipeline activities.

• Expectation of sequential revenue growth and ramp-up in the second half of the year.

Commercial strategy and market access

• Launched product in September 2023, with a field force of 50 dermatology reps, 20 pediatric reps, and 8 institutional reps targeting key markets.

• Achieved 228 million commercially covered lives, with 55% requiring no prior authorization.

• Permanent J-Code published in April, streamlining reimbursement and driving a 42% increase in buy-and-bill accounts.

• Majority of plans cover the product as a medical benefit, providing financial incentives for providers.

• Early and strong demand from pediatricians led to accelerated hiring of pediatric sales reps.

Product differentiation and competitive landscape

• YCANTH is the first FDA-approved, painless treatment for molluscum contagiosum, addressing a market of 6 million annual cases.

• Successfully reduced compounded cantharidin competition, with major importers ceasing U.S. sales as of May 1.

• New competitor Zelsuvmi (nitric oxide, take-home) launching in H2 2024, but YCANTH offers clinician-administered, revenue-generating advantages.

• Seasonality expected, with higher molluscum cases in warmer months.